1. Home
  2. MYGN vs PAR Comparison

MYGN vs PAR Comparison

Compare MYGN & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$6.91

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Logo PAR Technology Corporation

PAR

PAR Technology Corporation

HOLD

Current Price

$35.74

Market Cap

1.4B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
PAR
Founded
1991
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Office Equipment/Supplies/Services
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
625.5M
1.4B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
MYGN
PAR
Price
$6.91
$35.74
Analyst Decision
Buy
Strong Buy
Analyst Count
12
5
Target Price
$11.82
$64.00
AVG Volume (30 Days)
1.1M
626.2K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$825,300,000.00
$440,451,000.00
Revenue This Year
$0.10
$30.40
Revenue Next Year
$5.28
$12.01
P/E Ratio
N/A
N/A
Revenue Growth
0.21
39.88
52 Week Low
$3.76
$31.65
52 Week High
$15.47
$81.51

Technical Indicators

Market Signals
Indicator
MYGN
PAR
Relative Strength Index (RSI) 45.85 49.40
Support Level $7.15 $33.29
Resistance Level $7.43 $38.15
Average True Range (ATR) 0.28 1.46
MACD -0.02 0.30
Stochastic Oscillator 9.50 46.96

Price Performance

Historical Comparison
MYGN
PAR

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

Share on Social Networks: